The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 375.00
Bid: 360.00
Ask: 374.00
Change: 11.00 (3.02%)
Spread: 14.00 (3.889%)
Open: 375.00
High: 375.00
Low: 375.00
Prev. Close: 364.00
WIL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wilmington plc Pre-close Trading Update

28 Jun 2019 07:00

RNS Number : 7299D
Wilmington PLC
28 June 2019
 

28 June 2019

 

Wilmington plc

('Wilmington', 'the Group' or 'the Company')

Pre-close Trading Update

 

Wilmington plc, the provider of information, education and networking services in Risk & Compliance, Healthcare and Professional knowledge areas, today announces a pre-close trading update for the year to 30 June 2019.

 

Trading Update

 

The Board is pleased to announce that underlying trading is broadly in line with the full year expectations set out at the start of the financial year. After a strong Q3, with organic revenue growth levels that were in excess of those expected, Q4 is likely to be approximately flat year on year, such that full year organic revenue growth will be positive, albeit towards the lower end of the previously anticipated low single digit range. Underlying costs are similarly at the lower end of expectations and hence on a comparable basis adjusted profit before tax is expected to be in line with previous guidance.

 

These results will be impacted by the adoption in the year of the IFRS 15 revenue recognition standard. As previously disclosed at the time of the interim results announcement in February, adoption of IFRS 15 for the year to 30 June 2018 had a £0.5m negative impact on previously reported full year revenue and adjusted EBITA. It is anticipated that the corresponding impact of adoption of IFRS 15 for the year to 30 June 2019 will be slightly higher than for the prior year due mainly to growth in revenue from on-line training programmes.

 

Cashflow generation in the second half of the year has been strong and expectations for year end net debt remain unchanged. Adoption of IFRS 15 has no impact on cash or cash generation.

 

The preliminary announcement of the Group's full year results to 30 June 2019 is expected to be published on 19 September 2019.

 

Divisional Commentary

 

Organic revenue growth for the full year in the Risk & Compliance division is expected to be in line with our mid-single digit growth aspiration. Good growth momentum has continued in the main Compliance business during H2 with strong demand for both on-line courses and in-house programmes.

 

In the Healthcare division, revenue performance has continued to improve, with an expectation that full year organic revenue growth will be around 1% with a stronger second half after the 5% organic decline in H1. The improvement comes partly from new business sales performance in the UK Healthcare business, which is expected to grow by mid-single digit percentage year on year. The second half in Healthcare has also seen a strong performance in US Healthcare due in part to a record attendance at the flagship RISE Nashville event that was held in March.

 

Market conditions for the Professional businesses have proved challenging in Q4 with the Brexit delay and uncertainties over the current political climate in the UK resulting in lower demand for training from legal and accountancy clients. This is expected to result in a low single digit organic decline in revenues for the Professional division for the full year after a flat first half. Recent investments in new products and internal systems means the division is well placed to benefit when market demand improves once the political situation is resolved and there is clarity on ongoing laws and regulations.

 

Board Update

 

As announced on 16 May 2019, the Board is pleased to welcome Mark Milner who will be joining the Group as Chief Executive Officer on 1 July 2019. At the same time, Martin Morgan, currently Interim Executive Chairman will revert to his previous position as Non-executive Chairman.

 

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement this inside information is now considered to be in the public domain.

For further information, please contact:

 

Wilmington plc 020 7490 0049

Martin Morgan, Interim Executive Chairman

Richard Amos, Chief Financial Officer

 

FTI Consulting 020 3727 1000

Charles Palmer / Dwight Burden / Leah Dudley

 

 

Notes to Editors

Wilmington plc is the recognised knowledge leader and partner of choice for information, education and networking in Risk & Compliance, Healthcare and Professional areas. Wilmington employs close to 1,000 people and has customers in 120 countries. Wilmington plc is a premium listed company on the main market of the London Stock Exchange.

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSEMFMWFUSEDM
Date   Source Headline
29th Sep 20179:27 amRNSDirector/PDMR Shareholding
27th Sep 20177:00 amRNSProposed Board Change
21st Sep 20171:47 pmRNSDirector/PDMR Shareholding
20th Sep 201711:50 amRNSShare Awards
18th Sep 20172:01 pmRNSVoting Rights and Capital
14th Sep 20172:48 pmRNSDirector/PDMR Shareholding
14th Sep 20179:33 amRNSDirector/PDMR Shareholding
13th Sep 20174:03 pmRNSDirector/PDMR Shareholding
13th Sep 20177:01 amRNSBoard Change
13th Sep 20177:00 amRNSFinal Results
22nd Aug 20171:52 pmRNSNotification of Final Results
18th Aug 20171:11 pmRNSHolding(s) in Company
1st Aug 201712:21 pmRNSVoting Rights and Capital
3rd Jul 20177:00 amRNSVoting Rights and Capital
28th Jun 20179:44 amRNSDirector/PDMR Shareholding
21st Jun 20173:05 pmRNSHolding(s) in Company
16th Jun 20174:35 pmRNSPrice Monitoring Extension
1st Jun 201712:00 pmRNSVoting Rights and Capital
19th May 201711:56 amRNSHolding(s) in Company
18th May 20177:00 amRNSTrading Statement
4th May 20177:00 amRNSProperty Disposal
3rd May 20171:56 pmRNSHolding(s) in Company
2nd May 20172:21 pmRNSVoting Rights and Capital
3rd Apr 201711:33 amRNSVoting Rights and Capital
1st Mar 20171:58 pmRNSVoting Rights and Capital
24th Feb 20172:29 pmRNSDirector/PDMR Shareholding
23rd Feb 20179:36 amRNSInterim Results - Update
23rd Feb 20177:00 amRNSInterim Results
1st Feb 20171:10 pmRNSVoting Rights and Capital
1st Feb 20177:00 amRNSCompletion of Health Service Journal
19th Jan 20177:04 amRNSAcquisition of Health Service Journal
18th Jan 20175:08 pmRNSHolding(s) in Company
17th Jan 20174:43 pmRNSHolding(s) in Company
12th Jan 20179:00 amRNSNotice of Interim Results
3rd Jan 201712:20 pmRNSTotal Voting Rights and Capital
16th Dec 20163:22 pmRNSHolding(s) in Company
1st Dec 20167:00 amRNSVoting Rights and Capital
3rd Nov 20164:03 pmRNSResult of AGM
3rd Nov 20167:00 amRNSAGM and Q1 Trading update
1st Nov 20167:00 amRNSVoting Rights and Capital
17th Oct 201612:53 pmRNSHolding(s) in Company
3rd Oct 201610:05 amRNSVoting Rights and Capital
21st Sep 20162:48 pmRNSDirector/PDMR Shareholdings
20th Sep 201611:54 amRNSShare Awards
16th Sep 20164:31 pmRNSReplacement: Share Awards and Options
16th Sep 20169:10 amRNSShare Awards and Options
14th Sep 20167:00 amRNSFinal Results
2nd Sep 20161:48 pmRNSHolding(s) in Company
1st Sep 20169:39 amRNSVoting Rights and Capital
11th Aug 201610:31 amRNSNotice of Final Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.